AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12818310 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in ratios
Number of subjects: 0
Study 11251396 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 120
Study 11251396 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 120
Study 8860279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use prevention intervention
Number of subjects: 0
Study 8860279 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tobacco and dietary intervention
Number of subjects: 0
Study 8860279 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification intervention
Number of subjects: 0
Study 8860279 — intervention group
Group type: COMPARATOR
Intervention: Dietary modification-only condition
Number of subjects: 0
Study 8860279 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 1637215 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium infusion (500 mL of 30% glucose containing 300 units of insulin and 5 g of potassium chloride at a rate of 1.66 mL.kg‐1.h‐1 for 1 hour before cardiopulmonary bypass)
Number of subjects: 0
Study 1637215 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium infusion
Number of subjects: 0
Study 1637215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6391736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-precipitated five-grass extract (Allpyral)
Number of subjects: 39
Study 6391736 — intervention group
Group type: COMPARATOR
Intervention: Two-grass conjugated extract (Conjuvac)
Number of subjects: 39
Study 6391736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Allpyral and Conjuvac)
Number of subjects: 39
Study 31570123 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness course (4-week duration)
Number of subjects: 52
Study 31570123 — intervention group
Group type: COMPARATOR
Intervention: Usual education (control group)
Number of subjects: 52
Study 30392525 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered Tumescent Local Anaesthesia (BT)
Number of subjects: 97
Study 30392525 — intervention group
Group type: COMPARATOR
Intervention: Standard Tumescent Local Anaesthesia (ST)
Number of subjects: 97
Study 30392525 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BT and ST)
Number of subjects: 97
Study 27233840 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT) - 21 mg daily maximum for 10 weeks
Number of subjects: 737
Study 27233840 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy Plus (NRT+) - 35 mg daily maximum patches and gum/inhaler for up to 22 weeks
Number of subjects: 737
Study 27233840 — intervention group
Group type: COMPARATOR
Intervention: Varenicline (VR) - 1 mg twice daily for up to 24 weeks
Number of subjects: 737
Study 24590752 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal lipid‐based nutrient supplements (LNS)
Number of subjects: 0
Study 24590752 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrient supplement
Number of subjects: 0
Study 21785956 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment program including massage therapy, ischemic pressure, aerobic exercise, and thermal therapy for 8 weeks
Number of subjects: 34
Study 21785956 — intervention group
Group type: COMPARATOR
Intervention: Control group continued medical treatment and participated in four educational sessions
Number of subjects: 34
Study 20346133 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification-based treatment
Number of subjects: 150
Study 20346133 — intervention group
Group type: COMPARATOR
Intervention: Usual care according to Dutch LBP guidelines
Number of subjects: 150
Study 17346248 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXCZ) 1200 mg daily for 17 days
Number of subjects: 10
Study 17346248 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 800 mg daily for 17 days
Number of subjects: 10
Study 16334861 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilayered skin construct (BSC)
Number of subjects: 31
Study 16334861 — intervention group
Group type: COMPARATOR
Intervention: Healing by secondary intention
Number of subjects: 31
Study 12516643 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark implants
Number of subjects: 28
Study 12516643 — intervention group
Group type: COMPARATOR
Intervention: ITI implants
Number of subjects: 28
Study 9709422 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique for obtaining rotational alignment during closed locked intramedullary nailing
Number of subjects: 0
Study 9709422 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods of judging alignment
Number of subjects: 0
Study 8596132 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM (5-fluorouracil, adriamycin, mitomycin C) regimen
Number of subjects: 26
Study 8596132 — intervention group
Group type: COMPARATOR
Intervention: ELF (etoposide, leucovorin, 5-fluorouracil) regimen
Number of subjects: 26
Study 8596132 — intervention group
Group type: COMPARATOR
Intervention: ELF regimen
Number of subjects: 26
Study 8596132 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM regimen
Number of subjects: 26
Study 2295264 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiabendazole
Number of subjects: 6
Study 2295264 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole
Number of subjects: 6
Study 582924 — intervention group
Group type: EXPERIMENTAL
Intervention: vincamine-cromesilate (Vincaryl)
Number of subjects: 26
Study 582924 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study 28651779 — intervention group
Group type: EXPERIMENTAL
Intervention: Below the artery (BA) technique
Number of subjects: 240
Study 28651779 — intervention group
Group type: EXPERIMENTAL
Intervention: Around the artery (AA) technique
Number of subjects: 240
Study 28651779 — intervention group
Group type: COMPARATOR
Intervention: Perineural (PN) technique
Number of subjects: 240
Study 28651929 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 361
Study 28651929 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 361
Study 28651929 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice (methotrexate, docetaxel, or cetuximab)
Number of subjects: 361
Study 28651929 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice
Number of subjects: 361
Study 26248851 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dialysate sodium concentration
Number of subjects: 96
Study 26248851 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysate sodium concentration
Number of subjects: 96
Study 24693626 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 0.1% zinc lactate and 0.01% allyl isothiocyanate
Number of subjects: 15
Study 24693626 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 15
Study 21389120 — intervention group
Group type: EXPERIMENTAL
Intervention: MHD intravenously (250 mg infused over 30 min)
Number of subjects: 12
Study 21389120 — intervention group
Group type: COMPARATOR
Intervention: OXC orally (one film-coated 300-mg tablet)
Number of subjects: 12
Study 18513390 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief self-management techniques
Number of subjects: 126
Study 18513390 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study 15767643 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once a day
Number of subjects: 385
Study 15767643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 11920979 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified treatment including mirror confrontation
Number of subjects: 0
Study 11920979 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 9865192 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy, pulsed CO2 laser
Number of subjects: 20
Study 9865192 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination CO2 and PDL laser treatment
Number of subjects: 20
Study 9865192 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser irradiation alone
Number of subjects: 20
Study 7846138 — intervention group
Group type: EXPERIMENTAL
Intervention: Traction
Number of subjects: 3
Study 2136969 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaritide (human atrial natriuretic peptide 102‐126) administered as 1‐hour infusions at a rate of 0.03 to 0.3 micrograms/kg/min
Number of subjects: 35
Study 2136969 — intervention group
Group type: COMPARATOR
Intervention: Anaritide (0.03 to 0.6 micrograms/kg/min)
Number of subjects: 35
Study 402543 — intervention group
Group type: EXPERIMENTAL
Intervention: Actihaemyl (0.5 ml per kg body weight)
Number of subjects: 88
Study 402543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludilat (200 mg)
Number of subjects: 88
Study 402543 — intervention group
Group type: EXPERIMENTAL
Intervention: Trental (200 mg)
Number of subjects: 88
Study 402543 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 88
Study 402543 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the substances investigated
Number of subjects: 88
Study 30980433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 94
Study 30980433 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 94
Study 27849400 — intervention group
Group type: COMPARATOR
Intervention: Q-switched neodymium:yttrium aluminum garnet (QSNd:YAG) laser at a fluence of 10 joule/cm2, 10 Hz and 2 mm spot size
Number of subjects: 60
Study 27849400 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium:yttrium aluminum garnet (Er:YAG) laser at 200-300 millijoule, 4 Hz and 2 mm spot size
Number of subjects: 60
Study 25349179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation for 6 months
Number of subjects: 691
Study 25349179 — intervention group
Group type: COMPARATOR
Intervention: Household income level
Number of subjects: 691
Study 24102928 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 3,600 mg/day
Number of subjects: 0
Study 24102928 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin enacarbil (GEn) 1,200 mg/day
Number of subjects: 0
Study 24102928 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 2,400 mg/day
Number of subjects: 0
Study 21576533 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mcg/d selenium supplementation
Number of subjects: 501
Study 21576533 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg/d selenium supplementation
Number of subjects: 501
Study 21576533 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mcg/d selenium supplementation
Number of subjects: 501
Study 21576533 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (all doses)
Number of subjects: 501
Study 21576533 — intervention group
Group type: COMPARATOR
Intervention: Yeast-based placebo
Number of subjects: 501
Study 19428401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 19
Study 19428401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 19
Study 19428401 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 19
Study 16460521 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-explanation with instruction
Number of subjects: 85
Study 16460521 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-explanation without instruction
Number of subjects: 85
Study 16460521 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct instruction with self-explanation
Number of subjects: 85
Study 16460521 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct instruction without self-explanation
Number of subjects: 85
Study 16460521 — intervention group
Group type: COMPARATOR
Intervention: Control (no self-explanation)
Number of subjects: 85
Study 14966737 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg/kg) administered for 72 hours, starting within 3 hours after surgery.
Number of subjects: 10
Study 14966737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no melatonin)
Number of subjects: 10
Study 14966737 — intervention group
Group type: COMPARATOR
Intervention: Healthy neonates (group 3)
Number of subjects: 10
Study 11708689 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-modal intervention (LEVITY) including brisk 20-minute outdoor walk at target heart rate of 60% of maximum heart rate, increased light exposure, and specific vitamin regimen.
Number of subjects: 112
Study 11708689 — intervention group
Group type: COMPARATOR
Intervention: Placebo vitamin (control group)
Number of subjects: 112
Study 9455079 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (TPS) 4 mg.kg‐1
Number of subjects: 38
Study 9455079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1 MAC)
Number of subjects: 38
Study 9455079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (2 MAC)
Number of subjects: 38
Study 7843869 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contact therapeutic touch (NCTT)
Number of subjects: 0
Study 7843869 — intervention group
Group type: COMPARATOR
Intervention: Mimic practitioners
Number of subjects: 0
Study 7843869 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki, LeShan, Intercessory Prayer
Number of subjects: 0
Study 3285834 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg torasemide
Number of subjects: 90
Study 3285834 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg torasemide
Number of subjects: 90
Study 3285834 — intervention group
Group type: COMPARATOR
Intervention: 100 mg furosemide
Number of subjects: 90
Study 3285834 — intervention group
Group type: COMPARATOR
Intervention: 200 mg furosemide
Number of subjects: 90
Study 30552280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with free HIV self-testing (HIVST) kits plus site-based HIV testing services.
Number of subjects: 210
Study 30552280 — intervention group
Group type: COMPARATOR
Intervention: Control group with site-based HIV testing services only.
Number of subjects: 210
Study 30552280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with free HIVST kits plus site-based HIV testing services.
Number of subjects: 210
Study 25897147 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 9326
Study 25897147 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 9326
Study 25897147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-frail
Number of subjects: 9326
Study 25897147 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail
Number of subjects: 9326
Study 25897147 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for baseline characteristics and GRACE covariates
Number of subjects: 9326
Study 25560051 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg once daily)
Number of subjects: 12
Study 25560051 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg once daily)
Number of subjects: 12
Study 25560051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23067229 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) for 12 weeks
Number of subjects: 76
Study 23067229 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) for 12 weeks in OLETF rats
Number of subjects: 76
Study 20671032 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral leg press eccentric exercise
Number of subjects: 27
Study 20671032 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral elbow flexor eccentric exercise
Number of subjects: 27
Study 18520293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib at 50 mg daily for 4 of 6 weeks
Number of subjects: 110
Study 18520293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib at 37.5 mg daily (continuous dosing schedule)
Number of subjects: 110
Study 15496230 — intervention group
Group type: COMPARATOR
Intervention: Serum insulin-like growth factor-1 levels in systemic lupus erythematosus patients
Number of subjects: 0
Study 15496230 — intervention group
Group type: COMPARATOR
Intervention: Serum somatostatin levels in older systemic lupus erythematosus patients (>55 yrs)
Number of subjects: 0
Study 15496230 — intervention group
Group type: COMPARATOR
Intervention: Serum growth hormone levels in systemic lupus erythematosus patients
Number of subjects: 0
Study 11358918 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported performance of MPWs
Number of subjects: 326
Study 11358918 — intervention group
Group type: EXPERIMENTAL
Intervention: National Malaria Eradication Programme and health education (male MPWs)
Number of subjects: 326
Study 11358918 — intervention group
Group type: EXPERIMENTAL
Intervention: Family welfare and immunization programmes (female MPWs)
Number of subjects: 326
Study 11358918 — intervention group
Group type: EXPERIMENTAL
Intervention: Key national health programmes (tuberculosis and acute respiratory infection)
Number of subjects: 326
Study 11358918 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of health problems of the elderly
Number of subjects: 326
Study 9748012 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor
Number of subjects: 250
Study 9748012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 7833100 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp hypothermia using Theracool cooling machine
Number of subjects: 35
Study 7833100 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp hypothermia
Number of subjects: 35
Study 3283804 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 48
Study 3283804 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 48
Study 3283804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31714895 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Citrulline 15 g/d for 2 weeks
Number of subjects: 41
Study 26757835 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3PUFA with SFA
Number of subjects: 0
Study 26757835 — intervention group
Group type: COMPARATOR
Intervention: n-3PUFA with n-6PUFA
Number of subjects: 0
Study 24451438 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS‐ICT group (n = 77)
Number of subjects: 154
Study 24451438 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CPR + UC)
Number of subjects: 154
Study 22492584 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose (50 g/day for 12 weeks)
Number of subjects: 110
Study 22492584 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (50 g/day for 12 weeks)
Number of subjects: 110
Study 20185006 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional and non-traditional risk factors
Number of subjects: 3675
Study 18030652 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 34
Study 18030652 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 34
Study 16236879 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2.0-g dose of azithromycin microspheres
Number of subjects: 499
Study 16236879 — intervention group
Group type: COMPARATOR
Intervention: Extended-release clarithromycin (1.0 g/d for 7 days)
Number of subjects: 499
Study 11322633 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% metoclopramide
Number of subjects: 18
Study 11322633 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% droperidol
Number of subjects: 18
Study 11322633 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 18
Study 9395150 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral (RUL) ECT
Number of subjects: 39
Study 9395150 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine treatment
Number of subjects: 39
Study 8198976 — intervention group
Group type: EXPERIMENTAL
Intervention: levamisole 2.5 mg kg‐1 day‐1 given for 2 days every week for 18 months
Number of subjects: 78
Study 8198976 — intervention group
Group type: COMPARATOR
Intervention: placebo therapy in the same schedule
Number of subjects: 78
Study 3579807 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic gas mixtures (FIO2 = 17.39%, 14.40%, 11.81%)
Number of subjects: 7
Study 30630487 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) in Center A
Number of subjects: 107
Study 30630487 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) in Center B
Number of subjects: 107
Study 30630487 — intervention group
Group type: COMPARATOR
Intervention: Control (no DA) in Center A and B
Number of subjects: 107
Study 27387759 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of oral antibiotics
Number of subjects: 107
Study 27387759 — intervention group
Group type: COMPARATOR
Intervention: No further antibiotic treatment (control)
Number of subjects: 107
Study 25234479 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased prefrontal cortex activation in ASD during face recognition task
Number of subjects: 31
Study 25234479 — intervention group
Group type: EXPERIMENTAL
Intervention: DLPFC activation in ASD
Number of subjects: 31
Study 25234479 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 31
Study 24165222 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) performed by trained nurses using Fibroscan to measure liver stiffness; cutoff score of 6.8 kPa or greater as an indicator of CLD with fibrosis.
Number of subjects: 495
Study 21792119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubular diskectomy
Number of subjects: 328
Study 21792119 — intervention group
Group type: COMPARATOR
Intervention: Conventional microdiskectomy
Number of subjects: 328
Study 19196360 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/160 mg
Number of subjects: 0
Study 19196360 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 0
Study 16924325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging plates
Number of subjects: 45
Study 16924325 — intervention group
Group type: COMPARATOR
Intervention: Interlocking nails
Number of subjects: 45
Study 15233977 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol
Number of subjects: 550
Study 15233977 — intervention group
Group type: EXPERIMENTAL
Intervention: carvedilol
Number of subjects: 550